Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKAA2 | P54646 | 12/20 | 0.56 |
| ▸ | PRKAB2 | O43741 | 5/20 | 0.56 |
| ▸ | PRKAG1 | P54619 | 5/20 | 0.56 |
| ▸ | PRKAA1 | Q13131 | 5/20 | 0.56 |
| ▸ | PRKAG3 | Q9UGI9 | 5/20 | 0.56 |
| ▸ | PRKAG2 | Q9UGJ0 | 5/20 | 0.56 |
| ▸ | PRKAB1 | Q9Y478 | 5/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | ACKR3 | P25106 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4609821 | 0.82 | KMT2A (0.54) | PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3 | |
| SCHEMBL506648 | 0.78 | ALDH1A1 (0.50) | PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3 | |
| SCHEMBL27747238 | 0.78 | P4HTM (0.51) | PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3 | |
| SCHEMBL18172850 | 0.76 | PARP1 (0.49) | PRKAA2SMN1; SMN2KMT2AKDM4EALDH1A1 | |
| SCHEMBL26066509 | 0.73 | PARP1 (0.43) | PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3 | |
| SCHEMBL519372 | 0.72 | PRKAA2 (1.00) | PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3 | |
| SCHEMBL5568167 | 0.72 | PRKAA2 (0.51) | PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3 | |
| SCHEMBL25153984 | 0.71 | PARP1 (0.76) | — | |
| SCHEMBL9908373 | 0.71 | SMYD3 (0.56) | PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3 | |
| SCHEMBL19496629 | 0.71 | CNR1 (0.62) | SMN1; SMN2NPC1RAB9AKMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1924265-A2 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | Genzyme Corporation (US) | 2008-05-28 | — | — | EP | disclosed |
| US-20070066624-A1 | Chemokine receptor binding compounds | ANORMED, INC. (CA) | 2007-03-22 | — | — | US | disclosed |
| WO-2007022371-A2 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | GENZYME CORPORATION (US) | 2007-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066624-A1 | Chemokine receptor binding compounds | CCR5, CCR4, CCR1 | PRKAA2 2195/4885PRKAB2 2160/4885PRKAG1 1820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.